NeuroSense CEO Details Phase 3 ALS Trial Plans, Canada Filing and Nasdaq Compliance EffortsTip Ranks·2 days ago, 10:17 AMNRSN+2.26%
NeuroSense Therapeutics publishes CEO shareholder letter on Phase 3 PrimeC plansPUBT·2 days ago, 09:57 AMNRSN+2.26%
NeuroSense prepares Canada new drug submission for PrimeC, targets December 2026 filingPUBT·2 days ago, 08:31 AMNRSN+2.26%
NeuroSense Issues CEO Letter to Shareholders | NRSN Stock NewsStockTitan·Aug 13 at 12:30 AMNRSN+2.26%
11:29 ETNeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canadaprnewswire·Aug 6 at 10:31 AMNRSN+2.26%
NeuroSense amends JonesTrading equity distribution agreement for up to $3.79 million share salesPUBT·Jul 31 at 03:16 PMNRSN+2.26%
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" | NRSN Stock NewsStockTitan·Jul 5 at 11:45 PMNRSN+2.26%
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS | NRSN Stock NewsStockTitan·Jun 29 at 12:30 AMNRSN+2.26%
